- Drug manufacturer’s recommendations to reduce risks associated with fingolimod.
| Monitoring parameter | When |
|---|---|
| Bradycardia | At least 6 hours after first dose |
| Pulse and blood pressure | Hourly during observation |
| Electrocardiograms (ECGs) | Prior to dosing and at end of observation |
| Ophthalmic examinations | Before and 3–4 months after treatment |
| Liver transaminase and bilirubin levels | Before initiation of therapy and within 6 months of initiation |
| Complete blood cells (CBC) | During treatment and for 2 months after discontinuation |